Superbugs – Clostridium Difficile and Klebsiella Pneumoniae: Recognition, Prevention and Treatment


Candice Shelton

Series: Allergies and Infectious Diseases
BISAC: MED022090

The first section of this book discusses Clostridium difficile Infections (CDI). There is no consensus on the definition of severe CDI, since it varies depending on the authors or clinical practice guidelines consulted. Severe CDI can be defined as an episode of CDI with one or more specific signs and symptoms of severe colitis or a complicated clinical course, with significant systemic toxicity and shock, requiring ICU admission or a colectomy, or resulting in death.

The chapters in this section examine the risk factors for the development of severe CDI; study the advances in fecal microbiota transplantation; and provide management strategies of CDI in intensive care units. Section Two of this book provides research on Klebsiella pneumoniae infections. Klebsiella pneumoniae producing KPC-type carbapenemase (KPC-Kp) is an emerging problem epidemiologically, diagnostically, and therapeutically. Carbapenem-resistant Klebsiella pneumoniae have emerged as a class of pathogens that pose a significant threat to patients admitted to healthcare facilities. The first chapter of this section reviews the molecular epidemiology of Klebsiella pneumoniae carbapenemase. The following chapters discuss KPC-Kp; Klebsiella pneumoniae brain abscess in adults; and the causes of Ankylosing spondylitis and Crohn’s disease.
(Imprint: Nova Biomedical)



Table of Contents


Section One: <i>Clostridium difficile</i> Infections

Chapter 1
Risk Factors for the Development of Severe <i>Clostridium difficile</i> Infection
(Álvaro Dubois, Mónica Mourelo, Rita Galeiras, David Freire, and Lidia Pita, Critical Care Unit. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidad de A Coruña (UDC), A Coruña, Spain)

Chapter 2
Advances in Fecal Micriobiota Transplantation
(Szabolcs Vigvári and Zoltán Péterfi, Department of Infectious Diseases, 1st department of Internal Medicine, University of Pécs, Pécs, Hungary)

Chapter 3
Intensive Care Unit Specific Management
(Lidia Pita, Rita Galeiras, David Freire and Mónica Mourelo, Critical Care Unit. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidad de A Coruña (UDC), A Coruña, Spain)

Section Two: <i>Klebsiella pneumoniae</i> Infections

Chapter 4
Molecular Epidemiology of <i>Klebsiella pneumoniae</i> Carbapenemase
(Daniela Jones-Dias, Manuela Caniça and Vera Manageiro, National Reference Laboratory of Antibiotic Resistances and Healthcare Associated Infections (NRL-AR/HAI), Department of Infectious Diseases, National Institute of Health Doctor Ricardo Jorge, Lisbon, Portugal)

Chapter 5
<i>Klebsiella pneumoniae</i> Producing KPC-Type Carbapenemase: From Bench to Bedside
(Francesco Sbrana, Emanuela Sozio, Bruno Viaggi and Carlo Tascini, Fondazione Toscana Gabriele Monasterio, Pisa, Italy, and others)

Chapter 6
<i>Klebsiella pneumoniae</i> Brain Abscess in Adults
(Yee-Huang Ku, Yin-Ching Chuang and Wen-Liang Yu, Division of Infectious Disease, Department of Internal Medicine, Chi Mei Medical Center-Liouying, Tainan City, Taiwan, and others)

Chapter 7
Ankylosing Spondylitis and Crohn’s Disease are Caused by <i>Klebsiella</i> Infections in the Gut
(Alan Ebringer, Taha Rashid and Clyde Wilson, Analytical Sciences Group, King’s College London, UK, and others)


Additional information